热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　康方生物（09926.HK）涨11.74%，市值202亿港元，公司今日发布新型肿瘤免疫治疗新药阶段性数据，并获大和首次覆盖，予目标价45港元。

　　大和发表研究报告，首次给予康方生物（09926）“买入”评级，给予目标价45元。该行认为市场低了估康方生物的双特异性抗体新药AK104（PD-1/CTLA-4bsAb）及其他候选药物的潜力。

　　该行指出，Nivolumab（PD-1 mAb）加上Ipilimumab（CTLA-4 mAb）是一种公认的联合疗法，而从理论上，对比安全性较佳的单克隆抗体，双特异性抗体应具有相似的功效，认为康方的AK104用于治疗恶性胸膜间皮瘤的数据亦反映该药有潜力。

　　大和指，康方生物有9种药物正在临床试验中，有3种药物即将进入临床试验，估计总峰值收入为350亿元人民币。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张海营

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.